Drug intelligence / Profile preview

SMR001

Development stage: Unknown
Lead developer: 未名生物医药
Modality: Recombinant Proteins and Enzymes
Administration: Ophthalmic, Topical

Overview

SMR001 is a recombinant human nerve growth factor (rhNGF) developed as an ophthalmic solution for the treatment of moderate to severe dry eye disease and also investigated for diabetic foot ulcers. The drug is designed to promote corneal nerve regeneration and improve ocular surface health by mimicking endogenous nerve growth factor activity. Clinical studies have evaluated its safety, tolerability, pharmacokinetics, and efficacy in both healthy volunteers and patients with dry eye disease[1][8]. The mechanism of action involves supporting neuronal survival and regeneration at the ocular surface.

Other names: recombinant human nerve growth factorrhNGF

Targets

NGFR (p75NTR)NTRK1 (Tropomyosin-related receptor kinase A)

Beyond the preview

Go deeper on SMR001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SMR001.

Explore the full profile